Research Keyword: antifungal drugs

Analysis of Susceptibility and Drug Resistance of Antifungal Agents in Aspergillosis and Mucormycosis Patients: A Systematic Review

mycolabadmin

This comprehensive study analyzed how well five major antifungal drugs work against common disease-causing fungi like Aspergillus and Mucorales. Researchers reviewed 96 studies examining over 16,000 fungal samples to understand resistance patterns. The findings show that different fungi respond better to different drugs—for example, Aspergillus flavus responds well to voriconazole, while amphotericin B works best against other Aspergillus species. This information helps doctors choose the most effective treatments for fungal infections in vulnerable patients.

Read More »

Toward the consensus of definitions for the phenomena of antifungal tolerance and persistence in filamentous fungi

mycolabadmin

Scientists have proposed clear definitions and testing methods for two drug-resistance phenomena in fungi that cause infections. Unlike typical drug resistance, tolerance and persistence allow fungi to survive antifungal medications but in different ways: tolerance affects most spores while persistence affects only a small fraction. By standardizing how these phenomena are tested using fungal spores and measuring how quickly drugs kill them, researchers can better understand treatment failures and develop better therapies.

Read More »

Aspergillus latus: A cryptic causative agent of aspergillosis emerging in Japan

mycolabadmin

Researchers in Japan discovered that a dangerous fungus called Aspergillus latus, previously unknown in the country, has been causing infections since at least 2013. This fungus is difficult to identify because it looks similar to other related species and is actually a hybrid created from two different Aspergillus species. The study found seven cases of this fungus in clinical samples and discovered that it is resistant to some common antifungal medications, making accurate identification crucial for proper patient treatment.

Read More »

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth

mycolabadmin

This study examines how Trikafta, a new cystic fibrosis medication, affects a common fungal lung infection (Aspergillus fumigatus). The researchers found that Trikafta doesn’t directly kill the fungus but does make it more susceptible to antifungal drugs and improves lung clearance. Surprisingly, at high concentrations, the medication actually reduced the immune response against the fungus in immune cells, suggesting the need for careful monitoring of patients on this therapy.

Read More »

Unraveling the Fungi–Cancer Connection

mycolabadmin

Fungi living in and around tumors play surprisingly important roles in cancer development and treatment response, yet they have been largely overlooked compared to bacteria. Different cancer types host specific fungal species that can promote tumor growth through immune suppression and toxin production. By better understanding and potentially targeting these tumor-associated fungi, researchers believe we could develop new combination treatments that enhance the effectiveness of existing cancer therapies.

Read More »

Deep Fungal Infection of the Skin with Two Rare Fungi in a Dog Being Treated with Immunosuppressant Therapy: A Case Report

mycolabadmin

An 8-year-old dog receiving long-term immunosuppressive medication for brain inflammation developed rare fungal skin infections caused by two unusual fungi not previously reported together in veterinary medicine. Diagnosis required multiple tests including tissue samples, staining techniques, and genetic testing. Despite treatment with antifungal medications and careful adjustment of immunosuppressive drugs, the infections did not improve, highlighting the difficult balance between fighting infections and controlling the underlying immune disease.

Read More »
Scroll to Top